Page last updated: 2024-10-19

phenol and Leukemia

phenol has been researched along with Leukemia in 3 studies

Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)

Research Excerpts

ExcerptRelevanceReference
"Syringic acid (SA) is an active carcinogenesis inhibitor; however, the low bioavailability and unstable functional groups hinder its activity."5.91In vitro and in silico perspectives to explain anticancer activity of a novel syringic acid analog ((4-(1H-1, 3-benzodiazol-2-yl)-2, 6-dimethoxy phenol)) through apoptosis activation and NFkB inhibition in K562 leukemia cells. ( Cheemanapalli, S; Iyyappan, Y; Kanagaraj, S; Mahesh, Y; Palaniappan, C; Yarrappagaari, S, 2023)
"Hydroquinone (HQ) produced renal adenomas in male F344 rats, and these tumors appeared to arise from areas of spontaneous progressive nephropathy; the nephropathy itself has been found to be enhanced by HQ."4.79Analysis of studies related to tumorigenicity induced by hydroquinone. ( English, JC; Verna, L; Whysner, J; Williams, GM, 1995)
"Syringic acid (SA) is an active carcinogenesis inhibitor; however, the low bioavailability and unstable functional groups hinder its activity."1.91In vitro and in silico perspectives to explain anticancer activity of a novel syringic acid analog ((4-(1H-1, 3-benzodiazol-2-yl)-2, 6-dimethoxy phenol)) through apoptosis activation and NFkB inhibition in K562 leukemia cells. ( Cheemanapalli, S; Iyyappan, Y; Kanagaraj, S; Mahesh, Y; Palaniappan, C; Yarrappagaari, S, 2023)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (66.67)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Cheemanapalli, S2
Palaniappan, C2
Mahesh, Y2
Iyyappan, Y2
Yarrappagaari, S2
Kanagaraj, S2
Whysner, J1
Verna, L1
English, JC1
Williams, GM1
Smith, MT1
Robertson, ML1
Yager, JW1
Eastmond, DA1

Reviews

2 reviews available for phenol and Leukemia

ArticleYear
Analysis of studies related to tumorigenicity induced by hydroquinone.
    Regulatory toxicology and pharmacology : RTP, 1995, Volume: 21, Issue:1

    Topics: Adenoma; Animals; Carcinogenicity Tests; Female; Humans; Hydroquinones; Kidney Neoplasms; Leukemia;

1995
Role of metabolism in benzene-induced myelotoxicity and leukemogenesis.
    Progress in clinical and biological research, 1990, Volume: 340B

    Topics: Animals; Benzene; Biotransformation; Bone Marrow; Catechols; Cells, Cultured; Cytochrome P-450 Enzym

1990

Other Studies

1 other study available for phenol and Leukemia

ArticleYear
In vitro and in silico perspectives to explain anticancer activity of a novel syringic acid analog ((4-(1H-1, 3-benzodiazol-2-yl)-2, 6-dimethoxy phenol)) through apoptosis activation and NFkB inhibition in K562 leukemia cells.
    Computers in biology and medicine, 2023, Volume: 152

    Topics: Antineoplastic Agents; Apoptosis; Humans; K562 Cells; Leukemia; Molecular Docking Simulation; Phenol

2023
In vitro and in silico perspectives to explain anticancer activity of a novel syringic acid analog ((4-(1H-1, 3-benzodiazol-2-yl)-2, 6-dimethoxy phenol)) through apoptosis activation and NFkB inhibition in K562 leukemia cells.
    Computers in biology and medicine, 2023, Volume: 152

    Topics: Antineoplastic Agents; Apoptosis; Humans; K562 Cells; Leukemia; Molecular Docking Simulation; Phenol

2023
In vitro and in silico perspectives to explain anticancer activity of a novel syringic acid analog ((4-(1H-1, 3-benzodiazol-2-yl)-2, 6-dimethoxy phenol)) through apoptosis activation and NFkB inhibition in K562 leukemia cells.
    Computers in biology and medicine, 2023, Volume: 152

    Topics: Antineoplastic Agents; Apoptosis; Humans; K562 Cells; Leukemia; Molecular Docking Simulation; Phenol

2023
In vitro and in silico perspectives to explain anticancer activity of a novel syringic acid analog ((4-(1H-1, 3-benzodiazol-2-yl)-2, 6-dimethoxy phenol)) through apoptosis activation and NFkB inhibition in K562 leukemia cells.
    Computers in biology and medicine, 2023, Volume: 152

    Topics: Antineoplastic Agents; Apoptosis; Humans; K562 Cells; Leukemia; Molecular Docking Simulation; Phenol

2023